BR112015013414A2 - derivados de naftiridona e seu uso no tratamento, melhora ou prevenção de uma doença viral - Google Patents
derivados de naftiridona e seu uso no tratamento, melhora ou prevenção de uma doença viralInfo
- Publication number
- BR112015013414A2 BR112015013414A2 BR112015013414A BR112015013414A BR112015013414A2 BR 112015013414 A2 BR112015013414 A2 BR 112015013414A2 BR 112015013414 A BR112015013414 A BR 112015013414A BR 112015013414 A BR112015013414 A BR 112015013414A BR 112015013414 A2 BR112015013414 A2 BR 112015013414A2
- Authority
- BR
- Brazil
- Prior art keywords
- viral disease
- amelioration
- prevention
- treatment
- naphthyridone derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
resumo "derivados de naftiridona e seu uso no tratamento, melhora ou prevenção de uma doença viral". a presente invenção refere-se a um composto tendo a fórmula geral (v), opcionalmente na forma de um sal, solvato, polimorfo, cofármaco, cocristal, profármaco, tautômero, racemato, enantiômero, ou diastereômero farmaceuticamente aceitável ou mistura dos mesmos, (v) que são úteis no tratamento, na melhora ou prevenção de uma doença viral. além disso, as terapias de combinação específicas são descritas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361750032P | 2013-01-08 | 2013-01-08 | |
PCT/EP2014/050168 WO2014108408A1 (en) | 2013-01-08 | 2014-01-07 | Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015013414A2 true BR112015013414A2 (pt) | 2017-07-11 |
Family
ID=50073147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015013414A BR112015013414A2 (pt) | 2013-01-08 | 2014-01-07 | derivados de naftiridona e seu uso no tratamento, melhora ou prevenção de uma doença viral |
Country Status (12)
Country | Link |
---|---|
US (3) | US9199987B2 (pt) |
EP (1) | EP2945945B1 (pt) |
JP (1) | JP2016504376A (pt) |
KR (1) | KR20150103672A (pt) |
CN (1) | CN104903319B (pt) |
BR (1) | BR112015013414A2 (pt) |
CA (1) | CA2894821A1 (pt) |
ES (1) | ES2597803T3 (pt) |
HK (1) | HK1211288A1 (pt) |
MX (1) | MX2015008292A (pt) |
RU (1) | RU2015132977A (pt) |
WO (1) | WO2014108408A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20230215T1 (hr) | 2015-04-28 | 2023-04-14 | Shionogi & Co., Ltd. | Supstituirani policiklički derivati piridona i njihov predlijek |
CA2984130C (en) | 2015-04-28 | 2021-07-20 | Shionogi & Co., Ltd. | Substituted polycyclic pyridone derivative and prodrug thereof |
RU2745071C2 (ru) * | 2015-12-15 | 2021-03-18 | Сионоги Энд Ко., Лтд. | Лекарственный препарат для лечения гриппа, характеризующийся тем, что в нем объединены ингибитор кэп-зависимой эндонуклеазы и лекарственное средство против гриппа |
SG11201900869QA (en) | 2016-08-10 | 2019-02-27 | Shionogi & Co | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5475109A (en) | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
US6559145B2 (en) * | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
EP1790638B1 (en) | 2004-09-15 | 2013-04-03 | Shionogi Co., Ltd. | Carbamoylpyridone derivative having hiv integrase inhibitory activity |
TW200716632A (en) | 2005-05-16 | 2007-05-01 | Gilead Sciences Inc | Integrase inhibitor compounds |
US20110166123A1 (en) * | 2008-01-07 | 2011-07-07 | Aardea Biosciences, Inc. | Novel compositions and methods of use |
EP2412708A4 (en) | 2009-03-26 | 2014-07-23 | Shionogi & Co | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE |
TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
WO2011000566A2 (en) | 2009-06-30 | 2011-01-06 | Savira Pharmaceuticals Gmbh | Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections |
WO2011041143A1 (en) | 2009-10-01 | 2011-04-07 | Merck Sharp & Dohme Corp. | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS |
-
2014
- 2014-01-07 JP JP2015551201A patent/JP2016504376A/ja active Pending
- 2014-01-07 US US14/149,381 patent/US9199987B2/en not_active Expired - Fee Related
- 2014-01-07 KR KR1020157016509A patent/KR20150103672A/ko not_active Application Discontinuation
- 2014-01-07 ES ES14703780.8T patent/ES2597803T3/es active Active
- 2014-01-07 BR BR112015013414A patent/BR112015013414A2/pt not_active IP Right Cessation
- 2014-01-07 CN CN201480004147.6A patent/CN104903319B/zh not_active Expired - Fee Related
- 2014-01-07 MX MX2015008292A patent/MX2015008292A/es unknown
- 2014-01-07 CA CA2894821A patent/CA2894821A1/en not_active Abandoned
- 2014-01-07 WO PCT/EP2014/050168 patent/WO2014108408A1/en active Application Filing
- 2014-01-07 EP EP14703780.8A patent/EP2945945B1/en not_active Not-in-force
- 2014-01-07 RU RU2015132977A patent/RU2015132977A/ru not_active Application Discontinuation
-
2015
- 2015-10-22 US US14/920,000 patent/US9505758B2/en not_active Expired - Fee Related
- 2015-12-08 HK HK15112100.5A patent/HK1211288A1/xx unknown
-
2016
- 2016-11-28 US US15/361,710 patent/US20170290834A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN104903319B (zh) | 2017-05-31 |
EP2945945A1 (en) | 2015-11-25 |
RU2015132977A (ru) | 2017-02-14 |
US20170290834A1 (en) | 2017-10-12 |
US20140194432A1 (en) | 2014-07-10 |
US20160039818A1 (en) | 2016-02-11 |
CN104903319A (zh) | 2015-09-09 |
HK1211288A1 (en) | 2016-05-20 |
ES2597803T3 (es) | 2017-01-23 |
JP2016504376A (ja) | 2016-02-12 |
WO2014108408A1 (en) | 2014-07-17 |
US9505758B2 (en) | 2016-11-29 |
US9199987B2 (en) | 2015-12-01 |
EP2945945B1 (en) | 2016-08-31 |
MX2015008292A (es) | 2016-06-02 |
KR20150103672A (ko) | 2015-09-11 |
CA2894821A1 (en) | 2014-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015012693A2 (pt) | derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
BR112014029016A2 (pt) | derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
BR112014029006A2 (pt) | derivados de 7-oxo-4,7-di-hidro-pirazolo[1,5-a]pirimidina que são úteis no tratamento, melhora ou prevenção de uma doença viral | |
BR112015018738A8 (pt) | compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
EA201650029A1 (ru) | Пиразолопиридины и пиразолопиримидины | |
BR112014001369A2 (pt) | derivados de ácido hidroxâmico de heteroarila e uso dos mesmos no tratamento, melhora ou prevenção de doença viral | |
BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
BR112015022643A2 (pt) | inibidores diidro-pirrolpiridinona | |
BR112015021983A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
BR112014026643A2 (pt) | derivados de imidazotiadiazol e imidazopirazina como inibidores de receptor 4 ativado por protease (par4) para o tratamento de agregação de plaqueta | |
EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
BR112014008412A2 (pt) | derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral | |
BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
BR112015020772A2 (pt) | compostos de pirimidina e piridina e seu uso | |
BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos | |
PH12016502353A1 (en) | Pharmaceutical composition | |
BR112015004523A2 (pt) | compostos de tetraciclina | |
BR112015026967A8 (pt) | fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica | |
TW201613577A (en) | Pharmaceutical combinations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
B06I | Technical and formal requirements: publication cancelled |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |